Alzheimer's Disease Program

About Biorchestra

Biorchestra is a private, preclinical-stage biotech founded in 2013, headquartered in Daejeon, South Korea, with a U.S. presence. The company is pioneering RNA interference (RNAi) and messenger RNA (mRNA) therapeutics for challenging neurological conditions, leveraging its proprietary brain-targeted delivery technology. Its strategy involves advancing internal programs while seeking partnerships to expand its platform's application. As a pre-revenue entity, its success hinges on clinical validation of its delivery system and pipeline candidates.

About VersaPeutics

VersaPeutics is a private, pre-revenue biotech startup founded in 2016, targeting significant challenges in neuroscience. The company is in the early stages of building its scientific team and research programs, with a focus on translating recent breakthroughs in neuroscience into novel therapeutics. Its initial pipeline aims at Alzheimer's disease, spinal cord injury, and neuropathic pain, representing areas with substantial market need and limited treatment options. As a nascent company, its near-term goals are centered on securing investment, advancing its research platform, and progressing its lead candidates toward the clinic.

About Herophilus

Herophilus is a private, pre-clinical stage biotech leveraging a proprietary platform of human brain organoids, high-throughput biology, and AI/ML to de-risk and accelerate CNS drug discovery. The company has established a pipeline targeting high-need neurological and psychiatric conditions, including Rett syndrome, Alzheimer's disease, and schizophrenia, starting from a patient-derived biobank. By generating deep phenotypic data from physiologically relevant human models, Herophilus aims to identify novel drug candidates with a greater probability of clinical success.

About Selonterra

Selonterra is a private, pre-revenue biotech startup pioneering a novel approach to neurodegenerative diseases. The company's platform integrates human genetics with gene expression network analysis to identify unexploited, druggable targets, with initial programs targeting Alzheimer's (APOE4) and Parkinson's disease (SNCA, LRRK2). Led by a team of experienced industry veterans, the company is advancing its lead small molecule compounds through lead optimization towards IND-enabling studies. Selonterra aims to develop accessible, convenient oral therapies that address the root causes of these devastating conditions.

About Porosome Therapeutics

Porosome Therapeutics is a private, preclinical-stage biotech founded in 2018 and based in San Diego. The company's core platform is built upon the foundational discovery of the porosome, a nanomachine responsible for cellular secretion, which it aims to structurally elucidate and therapeutically modulate using an integrated cryo-EM and AI approach. Its lead programs target the underlying secretory dysfunction in Alzheimer's disease and cystic fibrosis, proposing a novel mechanism beyond current standards of care. The company is pre-revenue and positioned at the intersection of structural biology, AI-driven drug discovery, and nanomachine therapeutics.

Therapeutic Areas

Other Alzheimer's Disease Drugs